Trial 5GYN-13-1


The MILO Study (MEK Inhibitor in Low-Grade Serous Ovarian Cancer): A Multi-National, Randomized, Open-Label Phase III Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Annie Yessaian, M.D.
Other Trial Staff:  Grace Facio, R.N., Marissa Aldana, D.M., Yanli Wang, D.M., Kristy Watkins, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.